Simran Padam

871 total citations · 1 hit paper
16 papers, 572 citations indexed

About

Simran Padam is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Economics and Econometrics. According to data from OpenAlex, Simran Padam has authored 16 papers receiving a total of 572 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 6 papers in Pulmonary and Respiratory Medicine and 6 papers in Economics and Econometrics. Recurrent topics in Simran Padam's work include Health Systems, Economic Evaluations, Quality of Life (5 papers), Advanced Breast Cancer Therapies (4 papers) and Ethics in Clinical Research (3 papers). Simran Padam is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (5 papers), Advanced Breast Cancer Therapies (4 papers) and Ethics in Clinical Research (3 papers). Simran Padam collaborates with scholars based in United States. Simran Padam's co-authors include Mina S. Sedrak, Jennifer Liu, Kevin George, Andrew R. Wong, Supriya G. Mohile, William Dale, Hyman B. Muss, Tanya M. Wildes, Andrea Lynch and Aminah Jatoi and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Annals of Oncology.

In The Last Decade

Simran Padam

15 papers receiving 569 citations

Hit Papers

Older adult participation in cancer clinical trials: A sy... 2020 2026 2022 2024 2020 50 100 150 200 250
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Older adult participation in cancer clinical trials: A systematic review of barriers and interventions
    2020 287 citations Mina S. Sedrak, Rachel A. Freedman et al. CA A Cancer Journal for Clinicians profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Simran Padam United States 7 266 166 161 133 113 16 572
Andrew R. Wong United States 5 146 0.5× 163 1.0× 157 1.0× 56 0.4× 96 0.8× 9 436
Amit Jethanandani United States 12 159 0.6× 114 0.7× 94 0.6× 115 0.9× 46 0.4× 28 513
Marika Rasschaert Belgium 12 261 1.0× 74 0.4× 72 0.4× 109 0.8× 209 1.8× 32 545
Naimish Pandya United States 10 226 0.8× 44 0.3× 199 1.2× 78 0.6× 47 0.4× 20 473
D. Galdermans Belgium 14 374 1.4× 138 0.8× 44 0.3× 444 3.3× 103 0.9× 35 781
Gábor Liposits Denmark 12 373 1.4× 51 0.3× 46 0.3× 162 1.2× 128 1.1× 48 586
Björn Penninckx United Kingdom 5 160 0.6× 57 0.3× 71 0.4× 93 0.7× 146 1.3× 7 378
AH Partridge United States 6 307 1.2× 77 0.5× 73 0.5× 103 0.8× 69 0.6× 30 754
Yat Ming Lau China 7 142 0.5× 52 0.3× 55 0.3× 89 0.7× 118 1.0× 13 350
Andres F. Espinoza United States 10 88 0.3× 113 0.7× 92 0.6× 67 0.5× 47 0.4× 41 408

Countries citing papers authored by Simran Padam

Since Specialization
Citations

This map shows the geographic impact of Simran Padam's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Simran Padam with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Simran Padam more than expected).

Fields of papers citing papers by Simran Padam

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Simran Padam. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Simran Padam. The network helps show where Simran Padam may publish in the future.

Co-authorship network of co-authors of Simran Padam

This figure shows the co-authorship network connecting the top 25 collaborators of Simran Padam. A scholar is included among the top collaborators of Simran Padam based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Simran Padam. Simran Padam is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Yuan, Yuan, Jin Sun Lee, Susan E. Yost, et al.. (2021). Phase I/II trial of palbociclib, pembrolizumab and letrozole in patients with hormone receptor-positive metastatic breast cancer. European Journal of Cancer. 154. 11–20. 61 indexed citations
2.
Yuan, Yuan, Jin Sun Lee, Susan E. Yost, et al.. (2021). Phase II study of neratinib in older adults with HER2 amplified or HER2/3 mutated metastatic breast cancer. Journal of Geriatric Oncology. 12(5). 752–758. 6 indexed citations
3.
Loh, Kah Poh, Vivian Lam, Simran Padam, et al.. (2021). Characteristics Associated With Functional Changes During Systemic Cancer Treatments: A Systematic Review Focused on Older Adults. Journal of the National Comprehensive Cancer Network. 19(9). 1055–1062. 21 indexed citations
4.
Liu, Jennifer, Simran Padam, Daneng Li, et al.. (2020). Strategies to Improve Participation of Older Adults in Cancer Research. Journal of Clinical Medicine. 9(5). 1571–1571. 17 indexed citations
5.
Sedrak, Mina S., Rachel A. Freedman, Harvey Jay Cohen, et al.. (2020). Older adult participation in cancer clinical trials: A systematic review of barriers and interventions. CA A Cancer Journal for Clinicians. 71(1). 78–92. 287 indexed citations breakdown →
6.
Lee, Jin Sun, Susan E. Yost, Tracey Stiller, et al.. (2020). Tolerability of neratinib in older adults with HER2 positive or HER2 mutated metastatic breast cancer.. Journal of Clinical Oncology. 38(15_suppl). e13018–e13018. 1 indexed citations
7.
Yuan, Yuan, Sarah K. Highlander, Susan E. Yost, et al.. (2020). Abstract P5-06-26: Gut microbiome profiling of patients with metastatic breast cancer undergoing immune checkpoint inhibitor therapy. Cancer Research. 80(4_Supplement). P5–6. 1 indexed citations
8.
Lam, Vivian, Kah Poh Loh, Simran Padam, et al.. (2020). Patient factors associated with changes in functional status during systemic cancer therapy in older adults: A systematic review.. Journal of Clinical Oncology. 38(15_suppl). e24022–e24022. 1 indexed citations
9.
Yuan, Yuan, Jin Sun Lee, Susan E. Yost, et al.. (2020). A Phase II Clinical Trial of Pembrolizumab and Enobosarm in Patients with Androgen Receptor-Positive Metastatic Triple-Negative Breast Cancer. The Oncologist. 26(2). 99–e217. 60 indexed citations
10.
Wong, Andrew R., Virginia Sun, Kevin George, et al.. (2020). Barriers to Participation in Therapeutic Clinical Trials as Perceived by Community Oncologists. JCO Oncology Practice. 16(9). e849–e858. 56 indexed citations
11.
Yuan, Yuan, Susan E. Yost, Jin Sun Lee, et al.. (2020). Abstract P3-11-04: A phase II study of pembrolizumab, letrozole and palbociclib in patients with metastatic estrogen receptor positive breast cancer. Cancer Research. 80(4_Supplement). P3–11. 3 indexed citations
12.
Sedrak, Mina S., Supriya G. Mohile, Virginia Sun, et al.. (2019). Barriers to clinical trial enrollment of older adults with cancer: A qualitative study of the perceptions of community and academic oncologists. Journal of Geriatric Oncology. 11(2). 327–334. 54 indexed citations
13.
Sedrak, Mina S., Arti Hurria, Virginia Sun, et al.. (2019). Social media for oncology clinical trial recruitment: Oncologists’ attitudes and perceptions.. Journal of Clinical Oncology. 37(15_suppl). e18066–e18066. 1 indexed citations
14.
Sedrak, Mina S., Arti Hurria, Daneng Li, et al.. (2019). Barriers to clinical trial enrollment of older adults with cancer: A systematic review.. Journal of Clinical Oncology. 37(15_suppl). e18130–e18130. 1 indexed citations
15.
Wong, Andrew R., Arti Hurria, Virginia Sun, et al.. (2019). Barriers and facilitators to oncology clinical trial accrual: Comparing perceptions of community and academic oncologists.. Journal of Clinical Oncology. 37(15_suppl). e18131–e18131.
16.
Yuan, Yuan, Simran Padam, Paul Frankel, et al.. (2018). Peripheral blood mononuclear cell biomarkers predict response to immune checkpoint inhibitor therapy in metastatic breast cancer. Annals of Oncology. 29. viii94–viii94. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Andrew R. Wong Breakdown of academic impact, for papers by Amit Jethanandani Breakdown of academic impact, for papers by Marika Rasschaert Breakdown of academic impact, for papers by Naimish Pandya Breakdown of academic impact, for papers by D. Galdermans Breakdown of academic impact, for papers by Gábor Liposits Breakdown of academic impact, for papers by Björn Penninckx Breakdown of academic impact, for papers by AH Partridge Breakdown of academic impact, for papers by Yat Ming Lau Breakdown of academic impact, for papers by Andres F. Espinoza
Rankless by CCL
2026